Anhui Sunhere Pharmaceutical Excipients 山河药辅
7 significant filings since 29 May 2026: 4 on share issue and 3 on dividend. The latest, on 1 Jul 2026: 关于2026年第二季度可转债转股情况的公告.
自 29 May 2026 起有 7 份重大公告：share issue 4 份、dividend 3 份。最新一份（1 Jul 2026）：关于2026年第二季度可转债转股情况的公告。
As of 25 Sep 2026 截至2026年9月25日
Anhui Sunhere Pharmaceutical Excipients 山河药辅, listed in 2015, operates in the chemical pharmaceuticals industry. The company reported revenue of RMB942.8m in 2025, up from RMB882.6m in 2024, with attributable net profit rising to RMB176.6m from RMB119.4m. Profit quality is supported by operating cash flow per share of RMB0.82 in 2025, ahead of net profit, at a ratio of 1.11x. Gross margin was 31.8% and net margin 18.4%, with ROE at 18.6%. As of 30 Jun 2026, liabilities to assets stood at 38.3%, current ratio at 3.82, and receivable and inventory days at 50 and 51, respectively. The actual controller and largest holder is 吴长虹, holding 20.17%. Receivable ageing, litigation case amounts, the order book, the auditor's opinion and key audit matters, and segment revenue are not shown. The stock has shown stable ownership and solid financial performance.
山河药辅于2015年上市，属于化学制药行业。2025年营业收入为9.43亿元，高于2024年的8.83亿元；归母净利润上升至1.77亿元，2024年为1.19亿元。2025年每股经营现金流为0.82元，经营现金流与净利润之比为1.11倍，显示盈利质量良好。2025年毛利率为31.8%，净利率为18.4%，净资产收益率为18.6%。截至2026年6月30日，资产负债率为38.3%，流动比率3.82，应收账款周转天数50，存货周转天数51。实际控制人及第一大股东为吴长虹，持股20.17%。应收账款账龄、诉讼案件金额、在手订单、审计意见及关键审计事项、分部收入未列示。公司财务表现稳健，股权结构稳定。
- Change in attributable net profit for the full year 2026
2026年全年归母净利润变动情况 - Operating cash flow to net profit ratio in 2026
2026年经营现金流与净利润之比 - Liabilities to assets ratio at year-end 2026
2026年末资产负债率
- Company: Anhui Sunhere Pharmaceutical Excipients 山河药辅, Shenzhen Stock Exchange 300452; industry Chemical Pharmaceuticals; listed 15 May 2015.
公司：山河药辅，深圳证券交易所 300452；行业：化学制药；上市日期：2015年5月15日。 - Close on 24 Sep 2026 RMB13.12; close on 24 Sep 2025 RMB13.04, RMB12.72 in today's terms; one-year change, adjusted for distributions and share changes +3.1%.
2026年9月24日收盘价13.12元；2025年9月24日收盘价13.04元（前复权12.72元）；一年涨跌幅（复权）+3.1%。 - 52-week range in today's terms, adjusted for distributions and share changes RMB11.40 to RMB16.44.
52周区间（前复权）11.40元至16.44元。 - In the last 12 months 2 trading days closed 9% or more above or below the day before (all days, not only this year). The 2 most recent of them: 19 Nov 2025 +9.0%; 15 Jan 2026 +20.0%. No two of the 2 fell on consecutive trading days.
近12个月共有2个交易日收盘涨跌幅达9%及以上（为全部交易日，不限于今年）。其中最近2个：2025年11月19日 +9.0%；2026年1月15日 +20.0%。其中任意两个交易日均不相邻。 - Market capitalisation RMB3.08bn; P/E TTM 17.1; price to book 3.06x.
总市值30.76亿元；市盈率（TTM）17.1；市净率3.06倍。 - Revenue 2025 RMB942.8m; 2024 RMB882.6m; change +6.8%.
营业收入2025年9.43亿元；2024年8.83亿元；同比+6.8%。 - Attributable net profit 2025 RMB176.6m; 2024 RMB119.4m; change +47.8%.
归属于母公司股东的净利润2025年1.77亿元；2024年1.19亿元；同比+47.8%。 - Net profit excluding non-recurring items, 2025 change +57.3%.
2025年扣除非经常性损益后的净利润同比+57.3%。 - Basic EPS 2025 RMB0.75; 2024 RMB0.51.
基本每股收益2025年0.75元；2024年0.51元。 - Operating cash flow per share 2025 RMB0.82; 2024 RMB0.50; operating cash flow to net profit 1.11x.
每股经营现金流2025年0.82元；2024年0.50元；经营现金流与净利润之比1.11倍。 - 2025 gross margin 31.8%; net margin 18.4%; ROE 18.6%.
2025年毛利率31.8%；净利率18.4%；净资产收益率18.6%。 - At 30 Jun 2026: liabilities to assets 38.3%; current ratio 3.82; quick ratio 3.49; receivable days 50; inventory days 51.
截至2026年6月30日：资产负债率38.3%；流动比率3.82；速动比率3.49；应收账款周转天数50；存货周转天数51。 - Period to 30 Jun 2026 (six months, not comparable with the full years above): revenue RMB521.6m, change +10.8%; attributable net profit RMB96.2m, change +3.4%; operating cash flow per share RMB0.39.
截至2026年6月30日的报告期（六个月，不可与上述全年数据直接比较）：营业收入5.22亿元，同比+10.8%；归母净利润9,618.9万元，同比+3.4%；每股经营现金流0.39元。 - Ownership: actual controller 吴长虹; largest holder at 30 Jun 2026: 吴长虹, 20.17%.
股权：实际控制人：吴长虹；2026年6月30日第一大股东：吴长虹，持股20.17%。 - Latest distribution: ex-date 10 Jun 2026, cash RMB0.30 per share.
最近一次分配：除权除息日2026年6月10日，每股现金0.30元。 - Aurelian Grade C, score 62.1 of 100, graded within a peer group of 158 companies in its industry; no rank among peers is given.
金源评级C，得分62.1（满分100），于行业同业158家中评定；未提供其在同业中的排名。 - Not held for this report: receivable ageing, litigation case amounts, the order book, the auditor's opinion and key audit matters, segment revenue.
本报告未掌握：应收账款账龄、诉讼案件金额、在手订单、审计意见及关键审计事项、分部收入。